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Previewspresent study, IL-4 derived from basophil
progenitors in LinSHIP-deficient bone
marrow cells were reported to mediate
IL-3-induced M2 macrophage differen-
tiation in mice (Kuroda et al., 2009).
Basophils also produce thymic stromal
lymphopoietin (TSLP), which amplifies
M2 polarization in allergic airway inflam-
mation (Han et al., 2013). Activated
basophils release histamine, which may
induce macrophages to express the
M2-related chemokine CCL22. Moreover,
M2 macrophages can release CCL24,
which is a basophil chemoattractant,
whereas activated basophils produce
CCL3, CCL4, and CCL5, which can
attract monocyte-macrophages, favor-
ing their dialog (Figure 1; Biswas and
Mantovani, 2010). Importantly, basophils
are a main source for early IL-4 produc-
tion in allergy and a possible initiator of
Th2 cell-mediated responses (Sokol and
Medzhitov, 2010). This raises the question
as to whether basophils display distinct
temporal roles in Th2 cell-mediated
inflammation, i.e., initiating Th2 cell
response in the early stage and attenu-
ating it through M2 macrophages in the
later stage. Further work will clarify this
and whether the basophil-macrophage
interactions described here is a general
paradigm or specific to particular Th2
cell-related situations.
How M2 macrophages dampen IgE-
CAI was not clear from the present410 Immunity 38, March 21, 2013 ª2013 Elsestudy. Although the contribution of argi-
nase-1, PD-L2, or immunosuppressive
cytokines was not favored, efficient
antigen uptake and clearance by M2
macrophages making antigen unavail-
able for basophil activation was sug-
gested. Another possibility arising from
the observation that basophils and
neutrophils show enhanced recruitment
in Ccr2/ skin lesions is whether M2
macrophages themselves may block
the recruitment of these cells, thereby
attenuating Th2 cell-mediated inflamma-
tion. Increased expression of chemo-
kines like CCL24 or CXCL8 by M2
macrophages (or basophils) may down-
regulate and desensitize their cognate
receptors on target cells, blocking their
recruitment.
In summary, the present study provides
an insight into monocyte-macrophage
differentiation during allergic skin in-
flammation demonstrating inflamma-
tory monocytes to differentiate into M2
macrophages, which then dampen
IgE-CAI. Importantly, the M2 skewing of
macrophages was mediated by baso-
phils, emphasizing that basophil-macro-
phage crosstalk presents a unique
paradigm in macrophage polarization,
which merits further investigation. Finally,
it is tempting to speculate whether
modulating basophil activation may be a
potential strategy to ‘‘reprogram’’ aber-
rant macrophages in disease settings,vier Inc.including cancer, where polarized macro-
phages have an ambivalent role.REFERENCES
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Ferguson et al. (2013) use applied physics to quantitate the fitness of HIV-1 Gag based on sequence
variability across the protein. This enables a new approach to vaccine design that focuses CD8+ T cell
responses on fitness-constrained parts of Gag.Considerable effort has been put into
defining the immune responses induced
by HIV-1 infection that are associated
with greatest viral control, with the
aim of reproducing the most effectiveresponses by prophylactic vaccination.
Human leukocyte antigen (HLA) Class I
proteins determine the specificity of
CD8+ T cell responses and, given that
certain HLA alleles are enriched in individ-uals who exhibit marked HIV-1 control
(elite controllers), the specificity of these
T cell responses must be important
for virus control. HIV-1 CD8+ T cell
responses are first observed in acute
Figure 1. Shifting HIV-1-Specific CD8 T Cell Immundominance through Vaccination
(A) HIV CD8+ T cell responses (solid colored lines) induced following HIV-1 infection expand unevenly. The immunodominant CD8+ T cell response often targets
highly variable regions of the HIV-1 proteome resulting in rapid escape (dotted) and limited fitness cost to the virus. T cells targeting more fitness constrained
HIV-1 regions from which escape is slow are also targeted but are often subdominant in acute infection. Some early virus control is observed in most subjects
but elite control (<50 cp/ml) is observed in <1% of individuals.
(B) One approach to HIV-1 vaccination is to redirect CD8+ T cell immundominance to regions of HIV-1 where escape imparts a significant fitness cost. The aim is
that following HIV-1 infection, preexisting vaccine-induced T cell responses would dominate over those induced by infection and CD8+ T cell selection pressure
maximized because virus escape would be constrained, resulting in greater virus control.
(C) Vaccination is unable to shift immunodominance in acute infection because of limited recognition of the infecting virus, poor population coverage because
epitopes numbers are limited in the immunogen, lower T cell frequencies, and/or escape, so virus control will not be effective.
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PreviewsHIV-1 infection, expanding strongly as
initial virus load (VL) declines (Figure 1,
top). The level of virus load set point is
established in the first 3–6 months ofinfection. This implies that the first HIV-1
CD8+ T cell responses in elite controllers
must contribute strongly to the lower
VLs ultimately observed. The converseImmunity 3is that in the majority of HIV-1 infected
individuals who have higher VLs, the first
CD8+ T cell responses induced after
infection fail to exert sufficient VL control.8, March 21, 2013 ª2013 Elsevier Inc. 411
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PreviewsVaccines may be able to correct the
latter.
Why are some HIV-1-specific T cell
responses more effective than others?
CD8+ T cells select escape mutants
during acute and chronic HIV infection.
These may be selected very rapidly or
more slowly. The strongest antiviral pres-
sure, resulting in rapid virus escape, is
exerted by the T cells that are immunodo-
minant, in the classical sense that they are
the highest magnitude responses at that
stage of infection (Liu et al., 2013). CD8+
T cell immunodominance hierarchies shift
as HIV-1 infection progresses largely
because of escape mutations. Changing
immunodominance patterns are unique
in every individual, but people who share
HLA alleles often target the same immu-
noprevalent epitopes though these may
not be immunodominant. Another key
factor in defining HIV-1 virus levels and
the rate of virus escape is the replicative
fitness of HIV-1 itself. Some T cell
epitopes lie in regions of the HIV-1 pro-
teome that are so functionally con-
strained, they endure CD8+ T cell
pressure for years without escape. Not
surprisingly, these epitopes are con-
served in sequence at the population level
and are often immunoprevalent amongst
individuals expressing protective HLA
alleles (Liu et al., 2013). If such conserved
epitopes could be identified in people
who do not have protective HLA types,
they could be targeted by vaccines.
So far, quantitative measures of HIV-1
fitness have only been possible in vitro
and have focused on specific epitopes
and individual amino acids. In this issue
of Immunity, Ferguson et al. (2013) bring
applied physics to the study of HIV-1 to
quantitate the fitness of HIV-1 in silico.
Their aimwas to define the fitness through
examining whole HIV-1 proteins, not just
reactive epitopes, which is important
because mutations outside reactive
T cell epitopes also impact virus fitness
and the ability of T cells to select escape
mutations (Crawford et al., 2007). Their
approach enables them to consider the
effect of multiple, ongoing mutations
across a protein with the view to more
accurately quantifying the ‘‘fitness land-
scape’’ of the protein. Ferguson et al.
(2013) developed an algorithm by using
amassed sequence data for HIV-1, largely
from the chronic stage of infection. They
focused on Gag proteins because of the412 Immunity 38, March 21, 2013 ª2013 Elselarge numbers of sequences available
and evidence that Gag is the target of
the most protective T cell responses.
They simultaneously examined the fre-
quency of having the most common
amino acid at each position of the protein
versus any other residue. Fitness pre-
dictions were made from the relative
frequency of these combinations in the
sequence database across the proteome.
Thus the most common sequence
patterns with the lowest ‘‘energy’’ are the
most fit. Despite the assumptions made,
that mutation at any position in and
around a T cell epitope has equal impact
on T cell recognition and that a fitness
cost is associated with all amino acids
that are not consensus, they were able
to validate their model by showing strong
correlations between fitness landscape
predictions and existing in vitro fitness
data looking at the impact of specific
escapes on virus replication in vitro. These
findings may have an interesting applica-
tion in studies of primary HIV-1 infection.
No study has yet fully explained the corre-
lation between VL decline in acute infec-
tion and the specificity, selective pres-
sure, or functional properties of the CD8+
T cells. The ‘‘quantitative landscape’’
approach should enable the intrinsic
fitness of the founder virus, certainly a
major contributor to virus load (Goepfert
et al., 2008; Mostowy et al., 2012), to be
factored in. Broader application for this
approach may be to identify novel sites
of fitness cost in other HIV-1 proteins
and in variable viruses such asHCVwhere
less in vitro fitness data are available.
The authors employed their method to
design novel CD8+ T cell immunogens
for vaccination. Their rationale, as also
proposed by others, is to induce immu-
nodominant CD8+ T cell responses to
epitopes that are immunoprevalent and
are slow to escape because of the fitness
cost associated with mutation. Following
HIV-1 infection, early T cell immunodomi-
nance would be shifted to these vaccine-
induced T cell responses, which would
then control VL prior to virus escape
(Figure 1, middle). The authors examined
many iterations of vaccine immunogens
proposing a 113aa immunogen con-
taining 12 T cell epitopes that best
accommodated their three criteria, fitness
cost on escape, maximum coverage of
their target population set at 45% of
Europeans with the most common HLAvier Inc.types, and minimization of the number of
epitopes.
How does this epitope-based ap-
proach differ from, and possibly add
to, other CD8+ T cell immunogen de-
signs? It is strongly distinctive from
whole-protein immunogens. These ap-
proaches use whole virus proteins to
maximize population level coverage and
T cell breadth. The whole protein antigen
is likely to be processed in the same
manner as the natural HIV antigen in
infected cells. They do not contain arti-
ficial linker sequences or junctional
sequences that may produce non-HIV-1
epitopes and possibly distort immunodo-
minance following vaccination. However,
compared with more focused vaccine
designs, any single whole protein immu-
nogens is a far from perfect match for in-
fecting virus and, as in natural infection,
is unlikely to induce early immundominant
T cell responses against fitness con-
strained epitopes. However, the whole-
protein approach has been improved by
the design of mosaic immunogens, which
include two or more alternative se-
quences at variable sites. These have
been shown in macaques to maximize
the breadth (number epitopes targeted)
and depth (cross reactivity to epitope vari-
ants) of the T cell responses induced by
vaccination to afford better coverage of
highly diverse incoming viruses (Barouch
et al., 2010). Although increased breadth
of T cell response does not guarantee
that the immunodominant T cell re-
sponses see the most fitness constrained
epitopes, if mosaic vaccines could induce
T cell responses that eradicated infected
cells very early following HIV-1 infection,
as has been described in 50% of vacci-
nated monkeys by Hansen et al. (2011),
this might not matter.
The approach of Ferguson et al. also
differs from other immunogen designs
that consist of conserved regions of
HIV-1 proteome rather than specific
T cell epitopes (Le´tourneau et al., 2007;
Rolland et al., 2007). Those approaches
aim to limit vaccine induced T cell
responses to sites of HIV-1 that are most
sequence constrained but do not limit
coverage to specific HLA haplotypes.
Like Ferguson et al., they aim to ensure
that early immunodominant CD8+ T cell
responses are made to conserved
epitopes (Figure 1, middle), in contrast to
natural infection where these are usually
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Previewsdelayed and subdominant (Figure 1, top).
A related immunogen design considers
immunoprevalent epitopes associated
with lower VL setpoints (Mothe et al.,
2011). Here, VL setpoint could be con-
sidered the cumulative output of CD8+
T cell mediated effects on virus fitness.
These epitopes often occur in the more
conserved regions of HIV-1, such as
Gag proteins so that virus escape from
these immunogens would also be
associated with fitness costs. Given the
common focus of these approaches on
conserved regions of HIV-1, it is not
surprising that several epitopes identified
in the Ferguson et al., epitope string have
also been identified in these other immu-
nogen designs. However, some new,
including more variable, epitopes were
defined. In vitro testing of the fitness
impact of mutations in these sites would
be further validation of the Ferguson
et al. approach and would also inform
whether these epitopes should be
included in other designs. Overall, the
strength of conserved immunogen
designs would be to shift immunodomi-
nace to key epitopes that prevent escape,
arguably allowing a wider time window
following natural infection for vaccination
induced T cells to control VL. The weak-
ness is that T cell breadth may be limited
or skewed to non-HIV-1 epitopes and
therefore result in poor population-level
immunogenicity.Ultimately, all HIV-1 vaccine designs
will work best when the founder virus is
very close to the consensus sequence,
but we know that does not always
happen. Indeed, even conserved epi-
topes in founder viruses often contain
both escape and compensating muta-
tions, generated in the patient’s sexual
partner (who has a different HLA type)
(Goepfert et al., 2008), which may take
months or years to revert. Moreover, it is
not at all clear whether shifting T cell im-
munodominance though vaccination can
be successfully achieved by a nonpersist-
ing vaccine that sets up T cell memory
several months to years previously. In
the worst-case scenario, the immuno-
genic stimulus of an incoming infection
may override these responses with little
beneficial effect (Figure 1, bottom). The
best case would be that the most favor-
able T cell responses become the first
T cell responses after infection (Fig-
ure 1, middle), which occurs only rarely
following natural infection (Figure 1, top)
even in those with protective HLA types.
Success of T cell vaccines against HIV-1
therefore depends not only on immu-
nogen design but also on whether the
vaccine vectors employed can induce
and sustain sufficient frequencies and
qualities of CD8+ T cells to enable early
virus control. The advent of applied
physics to help address these difficult
challenges is welcome.Immunity 3REFERENCES
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